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Abstract
Infection with Kaposi’s sarcoma associated herpesvirus (KSHV) has been linked to the development of primary effusion
lymphoma (PEL), a rare lymphoproliferative disorder that is characterized by loss of expression of most B cell markers and
effusions in the body cavities. This unique clinical presentation of PEL has been attributed to their distinctive plasmablastic
gene expression profile that shows overexpression of genes involved in inflammation, adhesion and invasion. KSHV-
encoded latent protein vFLIP K13 has been previously shown to promote the survival and proliferation of PEL cells. In this
study, we employed gene array analysis to characterize the effect of K13 on global gene expression in PEL-derived BCBL1
cells, which express negligible K13 endogenously. We demonstrate that K13 upregulates the expression of a number of NF-
kB responsive genes involved in cytokine signaling, cell death, adhesion, inflammation and immune response, including two
NF-kB subunits involved in the alternate NF-kB pathway, RELB and NFKB2. In contrast, CD19, a B cell marker, was one of the
genes downregulated by K13. A comparison with K13-induced genes in human vascular endothelial cells revealed that
although there was a considerable overlap among the genes induced by K13 in the two cell types, chemokines genes were
preferentially induced in HUVEC with few exceptions, such as RANTES/CCL5, which was induced in both cell types.
Functional studies confirmed that K13 activated the RANTES/CCL5 promoter through the NF-kB pathway. Taken collectively,
our results suggest that K13 may contribute to the unique gene expression profile, immunophenotype and clinical
presentation that are characteristics of KSHV-associated PEL.
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Introduction
Kaposi sarcoma-associated herpesvirus (KSHV) is directly
associated with Kaposi sarcoma and several lymphoproliferative
disorders (LPDs) including primary effusion lymphoma (PEL) and
multicentric Castleman’s disease (MCD) [1]. PEL is a highly
malignant plasmablastic tumor that most frequently affects body
cavities such as the pericardial or pleural spaces [1]. This clonal B
cell tumor is characterized by the lack of expression of most B and
T cell markers and thus has a ‘‘null phenotype’’ [1]. PEL cells
over-express genes involved in inflammation, cell adhesion and
evasion, which is believed to contribute to their unique presen-
tation in body cavities [2].
A hallmark of all herpesviruses is their ability to establish a
lifelong latent infection. Five major KSHV proteins are present in
the cells latently infected with the virus, including LANA (Latency
associated nuclear antigen), vCyclin, vFLIP (viral FLICE inhibi-
tory protein, also called K13), vIL6, and vIRF3 [3,4]. LANA,
vCyclin and vFLIP K13 are transcribed from the same genomic
region into a single tricistronic mRNA, which gets alternatively
spliced into three transcripts [5]. The K13 gene encodes for a
protein with homology to the prodomain of caspase 8/FLICE [6].
The K13 protein was originally thought to protect KSHV-infected
cells from apoptosis by preventing the activation of caspase 8/
FLICE and, as such, was classified as a viral FLICE inhibitory
protein (vFLIP) [6]. However, subsequent work from our
laboratory and others showed that K13 is a potent activator of
the NF-kB pathway and manipulates this pathway to promote
cellular survival, proliferation, transformation and cytokine
secretion [7,8,9,10,11,12,13,14,15].
To understand how viruses subvert host molecular pathways
and cause cellular transformation has been a fascinating and
challenging task. The advent of microarray technology has made it
feasible to perform whole genome expression profiling of different
disease states [16]. In the conventional method microarray data
analysis, only the top few individual genes that are highly
differentially expressed between two phenotypes are analyzed
[16]. Although such individual genes may prove to be relevant for
KSHV infection, it is increasingly doubted whether large fold
changes in individual genes have more biological relevance as
compared to smaller but coordinated fold changes in a set of genes
encoding proteins that belong to a single pathway [17]. As in
biological processes, genes often cooperate in the so-called
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the level of pathways might yield better insights into biological
mechanisms associated with the pathogenesis of a particular
disease [18]. In addition, integrating genes into functional sets
allow consideration of all genomic information available from a
microarray platform rather than focusing on individual genes
passing a certain significance threshold [17,19,20].
Previous work from our laboratory and others has shown that
ectopic expression of K13 in human umbilical vein endothelial
cells (HUVECs) induces them to acquire a spindle cell phenotype,
which is accompanied by exuberant production of pro-inflamma-
tory cytokines and chemokines known to be involved in the
pathogenesis of KS lesions [15,21]. Using gene expression analysis,
we further demonstrated that K13 may account for change in the
expression of a significant proportion of genes following KSHV
infection of vascular endothelial cells [22]. Although KSHV is also
associated with PEL and MCD very little is known about the effect
of K13 on gene expression in lymphoid cells. As such, in this study,
we have studied the effect of ectopic K13 expression on gene
expression and activation of signaling pathways in PEL-derived
BCBL1 cells, which express negligible K13 endogenously.
Furthermore, to determine whether K13 affects gene expression
differently between lymphoma and vascular endothelial cells, we
have compared our newly generated dataset of BCBL1 with our
publicly available microarray expression dataset of K13-expressing
HUVECs.
Materials and Methods
Cell lines and reagents
293T and BCBL1 cells were obtained from the American Type
Culture Collection. The IL-6 dependent murine T1165 plasma-
cytoma cell line has been described earlier [23]. Polyclonal
populations of BCBL1 cells expressing K13 and K13-ER
TAM have
been described previously [21,24]. FLAG antibody was purchased
from Sigma and mouse 8F6 monoclonal antibody against full
length K13 was generated in our lab as detailed previously [25].
NF-kB inhibitors Bay-11-7082, IKK inhibitor VI and PS-1145
were purchased from Calbiochem (San Diego, CA) and Arsenic
trioxide (As2O3) was from Sigma-Aldrich (St. Louis, MO).
Gene chip human array
We used the human genome HGU-133 plus 2.0 arrays
(Affymetrix, Santa Clara, CA); an oligonucleotide-probe based
gene array chip containing ,50,000 transcripts, which provides a
comprehensive coverage of the whole human genome.
RNA isolation and hybridization to Gene arrays
BCBL1 cells stably expressing empty vector MSCV or MSCV
K13-ER
TAM-encoding constructs were treated with 4OHT
(20 nM) or solvent for 48 h. Total RNA was isolated using
Qiagen RNeasy kit (Qiagen, Valencia, CA). Ten micrograms of
total RNA was used to synthesize cDNA. T7 promoter introduced
during the first strand synthesis was then used to direct cRNA
synthesis, which was labeled with biotinylated deoxynucleotide
triphosphate, following the manufacturer’s protocol (Affymetrix,
San Diego, CA). After fragmentation, the biotinylated cRNA was
hybridized to the gene chip array at 45uC for 16 h. The chip was
washed, stained with phycoerytherin-streptavidin, and scanned
with the Gene Chip Scanner 3000. After background correction,
data analysis was done using PLIER16 (probe logarithmic
intensity error) algorithm using Gene Spring GX11.0 (Agilent
Technologies, Santa Clara, CA). The microarray data has been
deposited with NCBI GEO database (GSE37355).
Luciferase reporter assay
A luciferase reporter plasmid containing the RANTES
promoter was kindly provided by Dr. Robert Schleliner (North-
western University). Expression constructs for K13 and K13-
58AAA and phosphorylation-resistant mutants of IkBa have been
described previously [7,26]. 293T cells were transfected in a 24-
well plate with various test plasmids along with the RANTES
luciferase reporter constructs (75 ng/well) and a pRSV/LacZ (a ˆ??-
galactosidase) reporter construct (75 ng/well), as described previ-
ously [27]. Cells were lysed 24-36 hours later, and cell extracts
were used to measure firefly luciferase and a ˆ-galactosidase
activities, respectively. Luciferase activity was normalized by the
a ˆ-galactosidase activity to control for differences in transfection
efficiency.
Gene set enrichment analysis (GSEA)
Nonparametric gene set enrichment analysis (GSEA) was
performed using GSEA 2.0 (Broad Institute, Cambridge, MA)
[19]. This method ranks genes according to their relative
difference in expression (Student’s t-statistic) between two pheno-
types of K13-ER
TAM cell (with and without 4OHT treatment).
GSEA compares this ranked list of genes to a large collection of
pathway data gene sets and assigns an enrichment score, if gene is
present in the dataset its score is increased and if it is absent the
score is decreased. The enrichment statistics is the maximum
deviation of running enrichment score from zero. The gene sets
that significantly perform the random-class permutations are
considered significant. A significance threshold was set at a
nominal p-value of 0.05 and a false discovery rate (FDR),0.20,
which is the estimated probability that a gene set with a given
enrichment statistic represents a false-positive finding. The gene
set with an FDR,0.20 indicates that the result is likely to be valid
8 out of 10 times.
Analysis of enrichment of Transcription Factor Binding
sites (TFBS)
Transcription factor (TF) binding sites show the highest density
around the transcription start site (TSS); therefore we restricted
our analysis to 1000 bp upstream and downstream of TSS site. We
used Biomart tool of Ensembl to retrieve 59 flanking regions of
each transcript. The conserved non-coding regions of the
promoters were searched for matches to all TFBS profiles both
in TRANSFAC [28] and JASPAR databases [29]. Briefly, while
searching both databases in TELiS (Transcription Element
Listening System), the parameters were set in order to set an
FDR,20% (TRANSFEC) or ,10% (JASPER) with correspond-
ing p,0.01. We also validated the JASPAR and TRANSFAC
predicted transcription factor binding sites in Matinspecter of
Genomatrix (Genomatrix, Munchen) as well as oPossum data
bases [30].
Real-time PCR
cDNA was synthesized from RNA samples by PCR RNA core
kit (Applied Biosystems, Bedford, MA). Real time quantitative
reverse transcript-polymerase chain reaction (qRT-PCR) was
performed with SYBER Green, using gene-specific PCR primers
listed in Table S1. Samples were run in triplicate, and PCR was
performed by an ABI Step One Plus thermocycler (Applied
Biosystems, Bedford, MA). To take into consideration any change
in the reference housekeeping gene, we used 4 representative
reference genes (GNBL, b-2-microglobulin, GAPDH and 18S
RNA) to calculate normalization factor (NF) using geNorm [31]
module in qbase
PLUSsoftware [32]. In addition, the efficiency (E)
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used to report relative expression of the gene of interest using 2
2DD
ct method as detailed earlier [33]. The statistical significance of
expression was calculated by two sided paired t-test and Pearson
Correlation coefficient between gene expression array and real
time PCR was calculated using R statistical software.
Cell viability and cell-cycle assays
To study the biological activity of K13-induced IL6 secretion,
the supernatants from untreated and 4OHT-treated BCBL1 cells
expressing vector and K13-ER
TAM cells were analyzed for the
growth of IL-6 dependent T1165 cells. T1165 cells from
exponentially growing cultures were washed three times with
hIL6-free medium and plated in a flat-bottom 96-well plate at a
density of 5610
3 cells/well in the presence or absence of BCBL1
supernatants or hIL6. Cell viability was measured after 48 hours
using the MTS reagent (3-4,5-dimethylthiazol-2yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) fol-
lowing manufacturer’s instructions (Promega, Madison, WI).
Absorbance of viable cells was measured at 490 nm with
600 nm as a reference wavelength. Percent cell survival was
calculated based on the reading of cells grown in the presence of
hIL6 as 100%. DNA content analysis was performed as described
previously [7]. Briefly, cell pellets were fixed in 70% ethanol, and
incubated at 4uC overnight. For staining, the cell pellets were re-
suspended in 0.5 ml of 0.05 mg/ml Propidium Iodide (PI) plus
0.2 mg/ml RNAseA and incubated at 37uC for 30 minutes. Cell
cycle distribution was analyzed on a BD Biosciences LSR II flow
cytometry instrument.
Enzyme linked Immunosorbent assay (ELISA)
Human CCL5 (RANTES) was measured in the cell culture
supernatant using a CCL5-ELISA kit from R&D systems
(Minneapolis, MN) and following the recommendations of the
manufacturer.
Results
Differential gene expression levels in BCBL1 -K13 cells
To study the impact of K13 on gene expression in PEL cells, we
took advantage of the PEL-derived BCBL1 cells as they express
negligible amount of K13 endogenously [24]. We had previously
generated BCBL1 cells stably expressing a K13-ER
TAM fusion
construct in which K13 is fused in-frame to the ligand -binding
domain of a mutated estrogen receptor [24]. The mutated
estrogen receptor does not bind to its physiological ligand
estrogen, but binds with very high affinity to the synthetic ligand
4OHT (4-hydroxytamoxifen) and regulates the activity of K13 in a
4OHT-dependent manner. The BCBL1 cells expressing either
mock vector or K13-ER
TAM were treated with 4OHT for
48 hours and RNA was harvested. High quality RNA was used
to run gene expression array using Affymetrix HG-U133 plus 2
chip representing more than 50,000 annotated transcripts.
Analysis of normalized fluorescence intensities indicated that in
the cells expressing empty vector, expression ratios of most of the
genes with and without 4OHT treatment remained close to 1 or
changed slightly (#2), suggesting that 4OHT by itself does not
have any significant effect on gene expression. In contrast,
induction of K13-ER
TAM expression by 4OHT treatment
changed the expression ratio of a significant proportion of genes
more than 2 fold (data not shown). Next, the gene array data was
uploaded to Gene Spring GX11.0 software, and after median shift
normalization the primary analysis was performed using PLIER16
algorithm, as recommended in the workflow of the software.
Table 1 enlists top 50 upregulated and 15 downregulated genes.
Among the genes upregulated by K13 were several known NF-kB-
responsive genes, such as BIRC3, TNFAIP3, EBI3, NFKBIA,
FAS, RELB and NFKB2. In contrast, CD19, a B cell marker, was
among the genes whose expression was down-regulated by K13. A
complete list of genes differentially expressed in 4OHT-treated
BCBL1-K13-ER
TAM cells is provided as Table S2.
Pathway enrichment in K13 expressing cells
We used a unique approach of defining the various biological
pathways affected by K13, where expression ratios of all the genes
in the dataset were used to divide genes in various sets in terms of
their biological relatedness. Gene set enrichment analysis (GSEA)
using pathway definitions from Biocarta gene sets database
revealed 9 significant gene sets specifically affected by K13
expression at a nominal p-value,0.05 and FDR,0.20. There are
several well-known pathways affecting the cellular growth and
cancer progression in these gene sets, such as Cytokine, Death,
NF-kB and Inflammatory pathways (Table 2). In a complemen-
tary approach, GSEA using pathway definitions from Kyoto
Encyclopedia of Genes and Genomes (KEGG) database revealed
10 gene sets significantly up-regulated in K13-expressing BCBL1
cells at a nominal p-value,0.05 and FDR,0.20. This analysis also
identified several pathways linked to immune and inflammatory
response and cell signaling, such as antigen processing and
presentation, apoptosis, adipo-cytokine signaling, Toll like recep-
tor signaling, cell adhesion molecules, epithelial cell signaling and
cytokine-cytokine receptor interaction pathways (Table 2). Thus,
despite the difference in definition of gene sets using the KEGG
and Biocarta databases, the pathways identified to distinguish
cellular responses attributed to K13 expression were comparable.
These well accepted and widely used databases not only differ in
their pathway definitions, but also offer different analyzable gene
sets. For example, the newly discovered HIV-NEF, NKT and
neutrophil-controlling FMLP pathways were not present, as such,
in the KEGG database, which could probably explain why they
were identified only in the GSEA using the Biocarta database.
Comparative Analysis of K13 induced genes in BCBL1 and
HUVEC cells
We have previously generated K13-ER
TAM expressing HU-
VEC and used them to study the effect of K13 on gene expression.
We compared our newly generated gene expression data set of
K13-ER
TAM expressing BCBL1 with our publically available gene
expression data set of K13-ER
TAM expressing HUVEC
(GSE16051) to determine if K13 affects genes differentially in
different cell lineages, which could explain, in part, the distinct
clinical presentations of clinical disorders associated with KSHV
infection. Among the genes showing .2 fold induction following
treatment with 4OHT, there were 42 genes that were shared
between the BCBL1 and HUVEC data sets (Table S3). For
example, Ubiquitin D was the most upregulated gene in 4OHT-
treated BCBL1-K13-ER
TAM cells and the second most upregu-
lated gene in 4OHT treated HUVEC-K13-ER
TAM cells. Addi-
tionally, genes belonging to the NF-kB, Cytokine and Inflamma-
tory, HIV-NEF and NKT pathways were enriched in both
datasets. Representative enrichment plots showing t-test for each
correlated gene in the ranked dataset for Cytokine, NF-kB and
inflammatory pathways are shown in Figure 1.
Although there was an overlap in the pathways activated by
K13 in BCBL1 and HUVEC cells, there was a significant
difference in the types and magnitude (fold induction) of genes
induced by K13 in the two cell types. Thus, 4OHT treatment
resulted in .20 fold induction of 14 genes in HUVEC-K13-
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TAM-transduced BCBL1 cells.
S.No. Entrez Gene Gene Symbol Gene Title RefSeq Transcript ID Fold change Regulation
1. 10537 UBD ubiquitin D NM_001470 26.07 Up
2. 5328 PLAU plasminogen activator, urokinase NM_001145031 19.66 Up
3. 5645 PRSS2 protease, serine, 2 (trypsin 2) NM_002770 14.84 Up
4. 330 BIRC3 baculoviral IAP repeat-containing 3 NM_001165 13.51 Up
5. 5644 PRSS1 protease, serine, 1 (trypsin 1) NM_002769 13.24 Up
6. 4050 LTB lymphotoxin beta (TNF superfamily,
member 3)
NM_002341 12.98 Up
7. 7128 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 NM_006290 12.85 Up
8. 154754 PRSS1 protease, serine, 1 (trypsin 1) NM_002769 12.56 Up
9. 7262 PHLDA2 pleckstrin homology-like domain, family A,
member 2
NM_003311 10.51 Up
10. 10148 EBI3 Epstein-Barr virus induced 3 NM_005755 9.90 Up
11. 4914 NTRK1 neurotrophic tyrosine kinase, receptor, type 1 NM_001007792 9.51 Up
12. 6352 CCL5 chemokine (C-C motif) ligand 5 NM_002985 9.42 Up
13. 4792 NFKBIA nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha
NM_020529 8.33 Up
14. 2015 EMR1 egf-like module containing, mucin-like,
hormone receptor-like 1
NM_001974 8.10 Up
15. 355 FAS Fas (TNF receptor superfamily, member 6) NM_000043 7.94 Up
16. 972 CD74 CD74 molecule, major histocompatibility
complex, class II invariant chain
NM_001025158 7.02 Up
17. 3117 HLA-DQA1 major histocompatibility complex, class II,
DQ alpha 1
NM_002122 6.73 Up
18. 259307 IL4I1 interleukin 4 induced 1 NM_152899 6.58 Up
19. 51700 CYB5R2 cytochrome b5 reductase 2 NM_016229 6.44 Up
20. 1543 CYP1A1 cytochrome P450, family 1, subfamily A,
polypeptide 1
NM_000499 6.01 Up
21. 25907 TMEM158 transmembrane protein 158 NM_015444 5.81 Up
22. 7273 TTN Titin NM_003319 5.21 Up
23. 84033 OBSCN obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEF
NM_001098623 5.17 Up
24. 7412 VCAM1 vascular cell adhesion molecule 1 NM_001078 5.07 Up
25. 9294 S1PR2 sphingosine-1-phosphate receptor 2 NM_004230 5.03 Up
26. 5971 RELB v-rel reticuloendotheliosis viral oncogene
homolog B
NM_006509 4.97 Up
27. 5996 RGS1 regulator of G-protein signaling 1 NM_002922 4.97 Up
28. 9308 CD83 CD83 molecule NM_001040280 4.94 Up
29. 3383 ICAM1 intercellular adhesion molecule 1 NM_000201 4.93 Up
30. 25801 GCA grancalcin, EF-hand calcium binding protein NM_012198 4.92 Up
31. 9235 IL32 interleukin 32 NM_001012631 4.81 Up
32. 8651 SOCS1 suppressor of cytokine signaling 1 NM_003745 4.75 up




34. 1999 ELF3 E74-like factor 3 (ets domain transcription
factor, epithelial-specific)
NM_001114309 4.68 Up
35. 3109 HLA-DMB major histocompatibility complex, class II,
DM beta
NM_002118 4.50 Up
36. 115019 SLC26A9 solute carrier family 26, member 9 NM_001142600 4.49 Up
37. 3561 IL2RG interleukin 2 receptor, gamma (severe
combined immunodeficiency)
NM_000206 4.48 Up
38. 4261 CIITA class II, major histocompatibility complex,
transactivator
NM_000246 4.34 Up
K13-Induced Genes in PEL
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TAM cells (Table S4). In contrast, only one gene, Ubiquitin D,
was induced .20 fold in 4OHT-treated BCBL1-K13-ER
TAM cells
(26.07 fold induction) (Table 1). Interestingly, although ubiquitin
D was the most upregulated gene in BCBL1-K13-ER
TAM cells
and the second most upregulated gene in HUVEC-K13-ER
TAM
cells, there was a significant difference in the magnitude of
induction (26.07 fold vs 61.02 fold) for this gene in the two cell
types. Furthermore, a majority of genes whose expression was
strongly induced by K13 in HUVECs were chemokines such as
CCL2 (73.04 fold), CCL20 (63.8 fold), CCL5 (49.7 fold), CXCL10
(53.32 fold), IL8 (18.4 fold), CX3CL1 (30.48 fold) and IL6 (17.57
fold) (Table S4). In contrast, CCL5 (9.4 fold) and IL32 (4.8 fold)
were the only chemokines whose expression was upregulated
greater than 4-fold by K13 in BCBL1 cells (Table 1). Interestingly,
suppressor of cytokine signaling 1 (SOCS1), a gene known to be
involved in dampening of inflammatory response was upregulated
4.75 fold by K13 in BCBL1 cells but not in HUVECs (Table S4).
Taken collectively, the above results demonstrate that although
K13 activates the NF-??e ˆB pathway in both BCBL1 cells and
HUVEC, it affects gene expression differentially in the two cell
lineages and strongly upregulates genes belonging to proinflam-
matory chemokines mainly in HUVECs.
Transcriptional control of K13-induced gene expression
It has been well established that genes with common
transcription factor (TF) binding sites have higher likelihood of
sharing similar expression profiles [34,35]. Indeed, it is a widely
accepted hypothesis that genes that are co-expressed share
common regulatory motifs [36,37,38]. Therefore, we next
examined if genes induced by 4OHT treatment in K13-ER
TAM
expressing BCBL1 and HUVECs were coordinately regulated by
common TFs. For this purpose, we searched the JASPER database
for TFs with binding sites over-represented in promoters of genes
upregulated by K13 in BCBL1 and HUVECs. In the newly
generated gene expression data set of 4OHT-treated BCBL1 K13-
ER
TAM -expressing cells, there were 6 transcription factors whose
binding sites were significantly over-represented in the promoters
of K13-induced genes according to the JASPER database
(p,0.01, FDR,0.10) (Table 3). Among these, three belonged to
Table 1. Cont.
S.No. Entrez Gene Gene Symbol Gene Title RefSeq Transcript ID Fold change Regulation
39. 4791 NFKB2 nuclear factor of kappa light polypeptide
gene enhancer in B-cells 2 (p49/p100)
NM_001077493 4.29 Up
40. 718 C3 complement component 3 NM_000064 4.29 Up
41. 285025 CCDC141 coiled-coil domain containing 141 NM_173648 4.29 Up
42. 100132999 LOC100132999 hypothetical protein LOC100132999 XM_001722799 4.16 Up
43. 6892 TAPBP TAP binding protein (tapasin) NM_003190 4.14 Up
44. 6236 RRAD Ras-related associated with diabetes NM_001128850 4.12 Up
45. 27074 LAMP3 lysosomal-associated membrane protein 3 NM_014398 3.99 Up
46. 2232 FDXR ferredoxin reductase NM_004110 3.98 Up
47. 3119 HLA-DQB1 major histocompatibility complex, class II, DQ
beta 1
NM_002123 3.77 Up
48. 114294 LACTB lactamase, beta NM_032857 3.70 Up
49. 64319 FBRS Fibrosin NM_001105079 3.70 Up
50. 780 DDR1 discoidin domain receptor tyrosine kinase 1 NM_001954 3.68 Up
51. 11124 FAF1 Fas (TNFRSF6) associated factor 1 NM_007051 3.31 Down
52. 55916 NXT2 nuclear transport factor 2-like export factor 2 NM_018698 2.74 Down
53. 51616 TAF9B TAF9B RNA polymerase II, TATA box binding
protein (TBP)-associated factor
NM_015975 2.71 Down
54. 2162 F13A1 coagulation factor XIII, A1 polypeptide NM_000129 2.63 Down
55. 3753 KCNE1 potassium voltage-gated channel, Isk-related
family, member 1
NM_000219 2.53 Down
56. 55737 VPS35 vacuolar protein sorting 35 homolog (S.
cerevisiae)
NM_018206 2.45 Down
57. 51474 LIMA1 LIM domain and actin binding 1 NM_001113546 2.43 Down
58. 135932 TMEM139 transmembrane protein 139 NM_153345 2.38 Down
59. 2844 GPR21 G protein-coupled receptor 21 NM_005294 2.34 Down
60. 930 CD19 CD19 molecule NM_001770 2.32 Down
61. 6711 SPTBN1 spectrin, beta, non-erythrocytic 1 NM_003128 2.30 Down
62. 2744 GLS Glutaminase NM_014905 2.29 Down
63. 3890 KRT84 keratin 84 NM_033045 2.23 Down
64. 54704 PPM2C protein phosphatase 2C, magnesium-
dependent, catalytic subunit
NM_018444 2.23 Down
65. 1131 CHRM3 cholinergic receptor, muscarinic 3 NM_000740 2.22 Down
doi:10.1371/journal.pone.0037498.t001
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S.No. Gene Set No. of genes in set ES NES NOMp-value FDR q-value RANKAT MAX
BCBL-K13 (a)-Biocarta
1 Cytokine pathway 20 20.70 21.82 0.007 0.087 1546
2 Death pathway 33 20.62 21.79 0.000 0.066 1824
3N F - kB pathway 23 20.68 21.76 0.005 0.062 1824
4 HIV Nef pathway 55 20.55 21.74 0.002 0066 2079
5 Inflammatory pathway 29 20.61 21.71 0.005 0.072 1546
6 NKT pathway 26 20.57 21.53 0.042 0.271 1709
7 FMLP pathway 35 20.52 21.53 0.028 0.237 2728
8 Stress pathway 24 20.56 21.51 0.025 0.240 3078
9 NTHI pathway 21 20.59 21.50 0.049 0.227 2824
BCBL-K13 (b)-KEGG
1 Antigen processing and
presentation
75 20.62 22.06 0.000 0.002 1538
2 Diabetes mellitus 41 20.65 21.92 0.000 0.010 2777
3 Apoptosis 83 20.57 21.89 0.000 0.011 2661
4 Adipocytokine signaling
pathway
72 20.56 21.86 0.000 0.015 3555
5 Toll like receptor signaling
pathway
100 20.51 21.76 0.000 0.041 2889
6 Cell adhesion molecules 125 20.49 21.74 0.000 0.044 3225
7 Small cell lung cancer 87 20.50 21.69 0.003 0.062 2889
8 Thyroid cancer 29 20.59 21.62 0.014 0.107 3555
9 Epithelial cell signaling 65 20.47 21.54 0.009 0.200 560
10 Cytokine cytokine receptor
interaction
244 20.40 21.53 0.001 0.196 1950
HUVEC-K13 (a)-Biocarta
1 Inflammatory pathway 29 20.86 22.21 0.000 0.000 486
2 Cytokine pathway 20 20.83 21.99 0.000 0.003 138
3 IL-1Receptor pathway 31 20.74 21.99 0.002 0.002 959
4N F - kB pathway 23 20.80 21.99 0.000 0.002 959
5 DC pathway 21 20.78 21.92 0.002 0.008 224
6 Toll pathway 33 20.68 21.81 0.006 0.029 1298
7 NTHI pathway 21 20.76 21.80 0.002 0.029 959
8 Death pathway 33 20.66 21.80 0.002 0.026 1712
9 HIV NEF pathway 55 20.61 21.78 0.002 0.029 2101
10 NKT pathway 26 20.69 21.75 0.013 0.036 800
11 IL-6 pathway 21 20.70 21.72 0.011 0.042 1766
12 IL-12 pathway 20 20.68 21.63 0.037 0.088 1446
13 Raccycd pathway 22 20.62 21.59 0.045 0.112 928
14 Stress pathway 24 20.60 21.51 0.074 0.180 949
HUVEC-K13 (b)-KEGG
1 Cytokine cytokine receptor
interaction
244 20.73 22.69 0.000 0.000 863
2 Antigen processing and
presentation
75 20.80 22.48 0.000 0.000 1246
3 Toll like receptor signaling
pathway
100 20.74 22.38 0.000 0.000 1053
4 Epithelial cell signaling 65 20.65 22.01 0.000 0.002 1170
5 Diabetes mellitus 41 20.73 22.00 0.000 0.001 1192
6 JAK STAT pathway 151 20.58 21.99 0.000 0.001 1766
7 Cell adhesion molecules 125 20.59 21.99 0.000 0.001 1025
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S.No. Gene Set No. of genes in set ES NES NOMp-value FDR q-value RANKAT MAX
8 Hematopoietic cell lineage 84 20.61 21.93 0.000 0.003 713
9 Adipocytokine signaling
pathway
72 20.60 21.84 0.000 0.010 1766
10 Small cell lung cancer 87 20.58 21.83 0.000 0.010 928
11 Aminosugars metabolism 29 20.66 21.69 0.019 0.051 1425
12 Apoptosis 83 20.54 21.69 0.004 0.047 1161
13 Natural killer cell mediated
cytotoxicity
127 20.49 21.65 0.004 0.062 2245
14 T cell receptor signaling
pathway
93 20.49 21.59 0.004 0.101 1755
doi:10.1371/journal.pone.0037498.t002
Figure 1. Gene set enrichment analysis. For Gene set enrichment analysis of signatures genes from BCBL1-K13 (top panel) and HUVEC-K13
(lower panel), the t-test was graphed for each correlated gene in the ranked dataset. Three GSEA enrichment plots for representative biological
pathways (Cytokine, NF-kB and Inflammatory) enriched in 4OHT-treated BCBL1-K13-ER
TAM and HUVEC-K13-ER
TAM are shown. The top portion of each
GSEA plot shows the running enrichment score for validated genes specific for particular pathway as it moves down the ranked list. The bottom
portion of each plot shows the value of ranking matrices as it moves down the list of ranked genes. The red horizontal bar which terminate with blue
color indicate shift from positively correlated genes (red) to negatively correlated genes (blue). Further detailed interpretation about these plots can
be found at Broad Institute web site (http://www.broadinstitute.org/gsea/index.jsp).
doi:10.1371/journal.pone.0037498.g001
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JASPAR database in BCBL1-K13 cells
S.No. Sequence motif Description p- value % of input
1 Jaspar NF-kappaB REL 2.16E-6 29.6
2 Jaspar p65 REL 0.0001 20.1
3 Jaspear Irf-1 TRP-cluster 0.0025 17.6
4 Jaspar CFI-USP Nuclear receptor 0.0027 16.4
5 Jaspar p50 REL 0.001 15.1
6 Jaspar COUP-TF Nuclear receptor 0.0030 4.4
7 Jaspar Irf-2 TRP-cluster 0.0088 2.6
TRANSFEC database in BCBL1-K13 cells
1 V$NFKAPPAB-01: NF-kappaB NF-kappaB 1.07E-5 27.7
2 V$NFKAPPAB65-01: NF-kappaB NF-kappaB (p65) 3.16E-5 24.5
3 V$NFKAPPAB50-01: NF-kappaB NF-kappaB (p50) 0.0002 17
4 V$NFKB-Q6: NF-kappaB NF-kappaB 0.0001 12
5 V$IK3-01: Ik-3 Ikaros 3 0.0012 8.8
6 V$COUP-01: COUP-TF COUP/HNF-4 heterodimer 0.0031 3.0
7 V$PAX2-01: Pax-2 Pax-2 0.0024 2.6
8 V$NRSF-01: NRSF neuron-restrictive silencer
factor
9.56E-6 1.2
JASPAR database in HUVEC-K13
1 Jaspar c-REL REL 1.00E-10 37.8
2 Jaspar NF-kappaB REL 3.99E-6 32.7
3 Jaspar Irf-1 TRP-Cluster 1.00E-10 26.5
4 Jaspar p65 REL 1.00E-10 22.5
5 Jaspar Dorsal-2 REL 4.84E-6 20.4
6 Jaspar p50 REL 0.0006 19.4
7 Jaspar c-FOS bZIP 0.0004 14.3
8 Jaspar Irf-2 TRP-Cluster 1.00E-10 11.2
9 Jaspar Brachyury T-BOX 0.0006 1.2
10 Jaspar COUP-TF Nuclear receptor 0.0088 1.1
TRANSFEC database in HUVEC-K13
1 V$NFKAPPAB-01: NF-kappaB NF-kappaB 2.19E-6 38.7
2 V$CREL-01: c-Rel c-Rel 0.0003 37.8
3 V$AP1-C: AP-1 AP-1 binding site 0.0008 37.7
4 V$STAT-01: STATx signal transducers and
activators of transcription
0.0003 32.8
5 V$NFKAPPAB65-01: NF-kappaB NF-kappaB (p65) 1.00E-10 28.6
6 V$NFKB-C: NF-kappaB NF-kappaB binding site 1.00E-10 19.4
7 V$NFKAPPAB50-01: NF-kappaB NF-kappaB (p50) 0.0005 19.4
8 V$NFKB-Q6: NF-kappaB NF-kappaB 1.00E-10 18.4
9 V$IRF1-01: IRF-1 interferon regulatory factor 1 1.00E-10 16.3
10 V$IRF2-01: IRF-2 interferon regulatory factor 2 1.53E-6 9.2
11 V$ISRE-01: ISRE interferon-stimulated response
element
0.0022 5.1
12 V$VMAF-01: v-Maf v-Maf 0.0013 3.1
13 V$TAXCREB-02: Tax/CREB Tax/CREB complex 1.00E-10 1.1
14 V$MEF2-01: MEF-2 myogenic enhancer factor 2 4.83E-5 1.1
(Genes upregulated more than 1.5-fold were analyzed using the JASPAR and TRANSFEC databases. Results with a p-value of less than 0.05 are shown. % input refers to
the number of gene promoters bearing the specific motif compared to total number screened.
doi:10.1371/journal.pone.0037498.t003
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we also searched the TRANSFAC database and similarly found
over-representation of binding sites for the members of the NF-
kB/REL family among the promoters of the genes induced by
K13 in BCBL1 cells. We next repeated the analysis with our
previously published HUVEC dataset. There were 10 sites that
were over-represented in JASPAR database using stringent
parameters (p,0.01, FDR,0.10), while 14 binding sites were
over-represented in TRANSFAC (p,0.01, FDR,0.15) database.
Similar to the BCBL1 dataset, NF-kB/REL binding sites were
again over-represented among the promoters of the genes induced
by K13 in HUVEC in both databases. Thus, consistent with our
published studies [9,27] and the results of the pathway analysis,
NF-kB/REL is the major transcription factor responsible for gene
induction by K13 in both BCBL1 and HUVECs. However, in
addition to NF-kB, several other TF binding sites were also over-
represented among the promoters of genes upregulated by K13.
Validation of in silico results
We validated our gene array data by determining mRNA
expression of twenty-five highly expressed genes (TRADD,
TNFSRF25, TNFSRF1B, RANTES/CCL5, SELE, CXCL10,
BID, NFKB1A, NFKB1, LTbR, VCAM, LMNB2, CTSS,
ALCAM, IL15, IL9, IL6, BIRC3, CIITA, HLADMB, IFNG,
HLADQB1, HLADQ1, GAS2 and CD74) belonging to the
cytokine, NF-kB, cell death, cell adhesion and antigen processing
pathways (Table S5). We found a good correlation with the
expression of the above as determined by real-time RT-PCR and
gene array data (Figure 2). As a control for the reliability of qRT-
PCR experiments, the mRNA expression of various housekeeping
genes such as GAPDH, 18S, GNBL, and b-2-microglobulin was
Figure 2. Validation of gene array data by qRT-PCR. (A) Twenty five genes from NF-kB, cytokine, and inflammatory pathways were randomly
selected and their relative mRNA levels in mock and 4OHT-treated vector and K13-ER
TAM-expressing BCBL1 cells were examined using qRT-PCR. Real-
time PCR reactions were performed in triplicate and the data presented as fold change mean 6S.E in target gene expression (*p,0.05; Student’s t-
test). (B) Pearson Correlation coefficient between gene expression array and real time PCR showed a significant agreement (Correlation coefficient
0.88; p,0.0001).
doi:10.1371/journal.pone.0037498.g002
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K13-ER
TAM -expressing cells remained unaltered (data not
shown).
K13-induced NF-kB pathway is known to be effectively blocked
by Bay-11-7082 and arsenic trioxide [13,39]. To examine the role
of the NF-kB pathway in the expression of K13-regulated genes in
BCBL1 cells, we studied the effect of Bay-11-7082 and arsenic
trioxide on 4OHT induced gene induction in BCBL1-K13-ER
cells by qRT-PCR analysis. As shown in Figure 3, pretreatment of
BCBL1 K13-ER
TAM cells with Bay-11-7082 and arsenic trioxide
effectively blocked the induction of TNFSRF1B, SELE, CXCL10,
NFKB1A, LMNB2, IL6, IFNG, CIITA, CTSS and CD74 genes
by 4OHT.
Mechanism of K13-induced RANTES/CCL5 upregulation
To study the mechanism by which K13 upregulates the
expression of genes in BCBL1 cells in greater detail, we selected
RANTES/CCL5 as a representative example since its expression
was also induced by K13 in HUVECs. RANTES is an important
protein involved in immunoregulatory, inflammatory and cell
proliferation pathways [40], making its mechanism of upregulation
by K13 of biological and clinical significance. We began by
validating the results of gene expression and qRT-PCR analyses
by checking the effect of K13 on RANTES expression at the
protein level. As shown in Figure 4A, we confirmed that expression
of RANTES was up-regulated in the supernatant of BCBL1-K13-
ER
TAM cells upon treatment with 4OHT, as determined by
ELISA.
To investigate the mechanism by which K13 upregulates
RANTES expression, human embryonic kidney 293T cells were
transfected with a luciferase-based reporter construct containing
the RANTES gene promoter. K13 strongly activated the
RANTES promoter as compared to empty vector-transfected
cells (Figure 4B). Since NF-kB pathway was identified as the major
Figure 3. NF-kB inhibitors block K13-regulated genes. BCBL1 K13-ER
TAM cells were treated with two NF–kB inhibitors (2 mM Bay 11-7082 or
2 mM As2O3) for 2 hours followed by 4OHT treatment for additional 24 hours and total RNA was isolated as described in the Materials and Method
section. Nine genes were randomly picked and their relative mRNA levels were examined using real-time RT-PCR as explained in Figure 2A.
doi:10.1371/journal.pone.0037498.g003
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JASPAR/TRANFAC database analysis, we next examined the
involvement of this pathway in K13-induced RANTES transcrip-
tional activation. For this purpose, we took advantage of a mutant
of K13, K13-58AAA, which lacks the ability to activate the NF-kB
pathway [7]. As shown in Figure 4C, K13-58AAA mutant failed to
activate the RANTES promoter. Furthermore, K13-induced
RANTES activity was effectively blocked by two phosphoryla-
tion-resistant mutants of IkBa (IkBa SS32/36AA and IkBaDN)
(Figure 4D–E) that are known to block the NF-kB pathway [27],
and by treatment with chemical inhibitors of the NF-kB pathway,
including Bay-11-7082 [13], IKK inhibitor VI [41], PS1145 [42]
and arsenic trioxide [39]. Collectively, these results confirm the
involvement of the NF-kB pathway in K13-induced up-regulation
of RANTES.
Biological consequences of K13-induced gene expression
We have previously shown that ectopic expression of K13 in
Rat1 fibroblast cells stimulates cellular proliferation [8] and its
shRNA-mediated silencing results in a block in cell proliferation
[9]. To study the biological consequences of K13 in PEL, we
studied the effect of 4OHT on cell cycle progression in BCBL1-
K13-ER
TAM cells. As shown in Figure 5A, 4OHT treatment of
serum-starved BCBL1-K13-ER
TAM cells resulted in an increase in
cells in the S-phase as compared to the untreated cells (24.6% vs
14.8%), suggesting that K13 stimulates cell-cycle progression from
G1 to S phase. Treatment with 4OHT had no significant effect on
cell cycle progression in the BCBL1-vector cells (data not shown).
The stimulatory effect of 4OHT on G1 to S phase transition was
blocked by treatment with Bay-11-7082, thereby confirming the
role of K13-induced NF-kB activation in this process (Figure 5A).
Figure 4. K13-induced NF-kB activity is critical for the activation of RANTES. (A) K13-induced up regulation of RANTES at protein level.
Cellular supernatant from BCBL1 vector and K13-ER
TAM cells treated with and without 4OHT were collected and used to measure the secretion of
RANTES by ELISA. The values shown are averages (mean 6 SE) of one representative experiment out of three in which the level of RANTES secretion
was measured in triplicate. (B–C) 293T cells were transfected with an empty vector, wild-type K13 (B) or K13-58AAA (C) (250 ng/well) along with a
RANTES promoter-driven luciferase constructs (75 ng/well) and a pRSV/LacZ (b-galactosidase) reporter construct (75 ng/well), and the reporter assay
performed as described under the Materials and Methods section. (D) Dominant-negative mutants of IkBa (IkBaDN and IkBaSS32/36AA) block K13-
induced RANTES promoter activity. 293T cells were transfected either with the indicated plasmids and reporter assay performed as described above.
The amount of IkBa mutant plasmids (500 ng/well) was five times the amount of vector or K13 (100 ng/well) plasmid and the total amount of
transfected DNA was kept constant by adding empty vector. (E) Pharmacologic inhibitors of NF-kB block K13-induced RANTES promoter activation.
293T cells were transfected with an empty vector or a vector encoding K13 along with RANTES-Luc and pRSV/LacZ reporter constructs.
Approximately 3 hours after transfection, cells were treated with dimethyl sulfoxide (vehicle) or the indicated compounds for 18 hours before cell
lysis and measurement of reporter activities. Reporter assay was performed as described for Figure 4B–C.
doi:10.1371/journal.pone.0037498.g004
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cells, K13 induced cytokine upregulation could contribute to the
pathogenesis of KSHV-associated malignancies by stimulating the
survival and proliferation of neighboring uninfected cells by acting
in a paracrine fashion. To test this hypothesis, we examined the
ability of conditioned supernatant from untreated and 4OHT-
treated BCBL1-K13-ER
TAM cells to support the survival of
murine T1165 plasmacytoma cell line that requires IL6 for
survival and proliferation [43]. As shown in Figure 5B, survival of
T1165 cells was reduced to approximately 6% when grown in IL6-
free medium for 72 hours. The addition of conditioned superna-
tant from untreated or 4OHT-treated BCBL1-vector cells
afforded minor protection against IL6-withdrawal-induced cell
death (approximately 25% cell survival), reflecting low-level
constitutive IL6 secretion from the BCBL1 cells. The conditioned
supernatant from untreated BCBL1-K13-ER
TAM cells similarly
resulted in only partial rescue from IL6-withdrawal-induced cell
death (Figure 5B). In contrast, conditioned supernatant from
4OHT-treated BCBL1-K13-ER
TAM cells markedly improved the
survival (77% survival) of T1165 cells, reflecting upregulation of
IL6 secretion by induction of K13 activity (Figure 5B). The
survival advantage conferred by the conditioned medium from
4OHT-treated BCBL1-K13-ER
TAM cells, however, disappeared if
the cells were treated with both 4OHT and Bay-11-7082,
confirming a role of K13-induced NF-kB in this process
(Figure 5B).
Discussion
PEL is a rare subset of non-Hodgkin’s lymphoma found in
patients with HIV/AIDS that predominantly grows in the body
cavities as neoplastic effusions, usually without a contiguous tumor
mass [44]. Morphologically, PEL shows features that bridge
immunoblastic and anaplastic large-cell lymphomas, and fre-
quently displays some degree of plasma cell differentiation [45].
We and others have demonstrated that K13 plays a key role in
constitutive NF-kB activity observed in PEL cells [9,46] and is an
oncogenic protein which contribute to lymphoproliferative disor-
ders [11,47,48]. In the present investigation, we provide a
comprehensive picture of global transcriptional changes induced
by K13 in PEL-derived BCBL1 cells. BCBL1 cells are infected
with KSHV but express very little K13 endogenously and have
negligible constitutive NF-kB activity [24,49]. As such, we chose
BCBL1 cells as a physiological relevant cell line to study the effect
of ectopic K13 expression on gene expression in lymphoid cells.
We observed that K13 upregulated the expression of a number
of NF-kB-responsive genes in BCBL1 cells. This observation was
confirmed by GSEA, qRT-PCR as well as analysis of JASPER and
TRANSFAC databases. Nuclear factor-kB (NF-kB) is a critical
transcription factor involved in the regulated expression of several
genes involved in the inflammatory and immune response [50].
Although many dimeric forms of NF-kB have been described, the
classical NF-kB complex is a heterodimer of the p65/RelA and
p50 subunits and is found in most cells in association with a family
Figure 5. Biological assays to study K13-induced IL6 production and cell cycle analyses. (A) A DNA content analysis showing significant
increase in S-phase of cell cycle by 4OHT treatment in serum-starved BCBL1 K13-ER
TAM cells and inhibition of this increase in S-phase cells by pre-
treatment with Bay-11-7082 (2 mM). DNA content analysis was performed as described previously [7] and explained in Materials and Method section.
(B) Cell survival of T1165 cells with supernatants from 4OHT-treated BCBL1-K13-ER
TAM cells. BCBL1 vector- and K13-ER
TAM cells were pretreated with
2 mM Bay-11-7082 for 2 hours followed by treatment with 4OHT for additional 72 hours and supernatants from these cells were collected and filtered.
T1165 cells were treated in triplicate in a 96 well plate (100 ml/well) with 20 ml of cell-free supernatant collected from cells described above. Seventy-
two hours post-treatment, cell viability of T1165 cells was measured by MTS assay as described in Materials and Method section. The values
(Mean6SEM) shown are from a representative of three independent experiments performed in triplicate.
doi:10.1371/journal.pone.0037498.g005
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shown that K13 activates the classical NF-kB pathway by
activating a multi-subunit IkB kinase (IKK) complex [53], which
contains two catalytic subunits, IKK1/IKKa and IKK2/IKKb,
and a regulatory subunit, NEMO/IKKc [52,54]. Activation of the
IKK complex by K13 results in phosphorylation of IkB proteins
which leads to their ubiquitination and proteasomal-mediated
degradation, allowing the classical NF-kB subunits to enter the
nucleus and turn on the expression of their target genes [53]. We
have also shown that K13 can also activate an alternate NF-kB
pathway [9] that involves IKK1/IKKa-mediated phosphorylation
of p100/NFKB2 and its slow proteasome-mediated processing
into the active p52/p49 subunit that culminates in kinetically
slower nuclear translocation of the p52-RelB NF-kB complex
[54,55]. Interestingly, NFKB2/p100 and RelB, the two NF-kB
subunits involved in alternate NF-kB pathway, were among the
genes upregulated by K13 in BCBL1 cells (Table 1). These results
suggest that, in addition to IKK1-induced p100 phosphorylation,
transcriptional upregulation of NFKB2 and RelB may also
contribute to the activation of the alternate NF-kB pathway by
K13.
We also observed significant upregulation of TNFAIP3 (A20)
and NFKB1A (IkBa) by K13 in BCBL1 cells. A20 is a
deubiquitinating enzyme that is known to act as a tumor
suppressor in several subtypes of non-Hodgkin and Hodgkin
lymphomas [56]. We have recently demonstrated that A20
blocked K13-induced NF-kB activity and K13-induced upregula-
tion of proinflammatory cytokines in a negative-feedback fashion
[49]. A20 was also shown to block K13- induced cellular
transformation [49]. In addition to A20, K13 upregulated the
expression of NFKB1A, which codes for IkBa, the negative
regulator of the classical NF-kB pathway that serves to keep the
p65/p50 heterodimers sequestered in an inactive state in the
cytoplasm [57]. Finally, the expression of SOCS1 (suppressor of
cytokine signaling 1), a negative regulator of the JAK/STAT [58]
signaling was significantly induced in the K13-expressing BCBL1
cells. The uncontrolled activation of the NF-kB and JAK/STAT
pathways has the potential of resulting in uncontrolled inflamma-
tory response. Therefore, induction of A20, IkBa and SOCS1 by
K13 in lymphoid cells may serve to attenuate the inflammatory
response and thus help maintain a balance between the virus and
the host.
In addition to the positive and negative regulators of the NF-kB
pathway, expression of RANTES/CCL5 was significantly upre-
gulated in K13-expressing BCBL1 and HUVECs. Further studies
utilizing a RANTES promoter-driven luciferase reporter construct
demonstrated that K13 upregulates RANTES through the NF-kB
pathway. RANTES is a powerful chemoattractant for blood
monocytes, memory T helper cells and eosinophils [59] and as
such may contribute to the inflammatory infiltrate present in
KSHV-associated malignancies. Additionally, RANTES/CCL5
has been shown to promote tumor proliferation, invasion,
metastases and angiogenesis [60] [61], which may also contribute
to the development of PEL and KS.
K13 also upregulated the expression of Epstein-Barr virus-
induced gene-3 (EBI-3), which associates with p28 to form
interleukin-27 (IL-27) or with IL-12 p35 to form IL-35. Both IL-
27 and IL-35 have immunosuppressive properties [62]. In
particular, IL-35 has been implicated in the suppressive function
of regulatory T cells (Treg), which contributes to infection
tolerance and tumor progression [62,63]. Thus, it is conceivable
that K13-induced upregulation of EBI-3 may not only contribute
to immune tolerance of KSHV-infected cells but also promote
progression of PEL and KS via generation of Tregs with
suppressive functions.
Another cytokine whose expression was upregulated by K13 in
BCBL1 cells was IL-32. A recent study demonstrated that the IL-
32 promoter contains NF-kB binding sites [64], which suggests
that, similar to the situation with RANTES/CCL5, K13 might
upregulate IL-32 through NF-kB activation. Interestingly, there is
a good correlation between IL-32 levels and HIV-1 replication in
lymphatic tissues and IL-32 was recently shown to play an
immunosuppressive role in lymphatic tissues during HIV-1
infection [65]. IL-32 was shown to induce the expression of
immunosuppressive molecules IDO (indole-amine-2,3-dioxygen-
ase) and Ig-like transcript 4 in immune cells, which not only block
immune activation but also impair host defenses [65]. It is
conceivable that the dampening of anti-viral immune response by
K13-induced IL-32 induction may enhance HIV-1 replication and
persistence, thereby resulting in a synergistic interaction between
HIV-1 and KSHV.
A comparative analysis of K13-induced genes in BCBL1 and
HUVEC revealed that although K13 primarily induced NF-kB
responsive genes in both cell types, there were significant
qualitative and quantitative differences. In particular, genes
belonging to cytokines and chemokines were highly and
differentially induced in HUVEC but not in the BCBL1 cells,
with few exceptions, such as RANTES/CCL5 and CXCL10.
The differential and robust induction of proinflammatory
chemokines and cytokines by K13 in HUVEC may account for
the presence of intense inflammatory infiltrate in KSHV
associated KS. The underlying reasons for the differential gene
induction by K13-induced NF-kB in the two cell types are not
clear, but may reflect the presence of lineage-specific positive and
negative regulators or epigenetic alterations. It is interesting to
note in this regard that SOCS1, a negative regulator of the
cytokine signaling, was upregulated only in the K13-expressing
BCBL1 cells.
In addition to the NF-kB pathway, genes belonging to a number
of other pathways, such as cytokine, death, inflammatory, and
antigen processing pathways, were found to be enriched among
K13-expressing BCBL1 cells and HUVECs. Similarly, JASPER
and TRANSFAC databases revealed the enrichment of a number
of transcriptional factors in addition to NF-kB among the
promoters of genes upregulated by K13 in BCBL1 and HUVECs.
However, there is considerable overlap among the genes induced
by the different signaling pathways and transcription factors. In
particular, NF-kB pathway is well known for its ability to induce
genes belonging to cytokine, death, antigen processing and
inflammatory pathways, and to work in concert with other
transcription factors, such as AP1 [66]. Therefore, it is conceivable
that enrichment of genes belonging to signaling pathways other
than the NF-kB pathway may simply reflect this overlap. We also
observed that K13 upregulates the expression of a number of
chemokines and cytokines, especially in HUVECs, which could
work in an autocrine/paracrine fashion to activate a number of
secondary signaling pathways and transcription factors, providing
an alternative explanation for our results. Studies are in progress to
delineate the role of K13 in activation of signaling pathways other
than the NF-kB pathway.
PEL display a gene expression profile that is distinct from all
non-Hodgkin lymphomas of immunocompetent hosts and AIDS-
associated NHL [67]. The gene expression profile of PEL has been
defined as plasmablastic as it shares features of both immunoblasts
and plasma cells [67]. Interestingly, increased expression of a
number of genes found to be induced by K13 in the BCBL1 cells
in the present study, including SOCS1, TNFAIP3, NFKB1A,
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and FAS, have been associated with the plasmablastic phenotype
in human lymphomas [68]. K13 also upregulated the expression of
IL6, a plasma cell growth factor that has been also shown to
stimulate the proliferation of PEL cells [69]. PEL cells are typified
by their lack of expression of B cell markers [48]. Interestingly,
CD19, a B cell marker, was one of the genes downregulated by
K13 in BCBL1 cells. Finally, PEL cells are defined by the over-
expression of genes involved in inflammation, cell adhesion and
invasion, which is believed to contribute to their presentation in
the body cavities [2]. Interestingly, in the present study, we
observed significant upregulation of genes belonging to all the
above categories upon K13 expression. Thus, K13 may contribute
to the unique gene expression profile and presentation in body
cavities that are characteristic of KSHV-associated PEL.
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